ClinicalTrials.gg
Active, not recruitingNCT04557618Updated Oct 27, 2026

Auricular VNS Following Subarachnoid Hemorrhage

An interventional study of Auricular Vagus Nerve Stimulation and Sham Auricular Vagus nerve Stimulation in Subarachnoid Hemorrhage, sponsored by Anna Huguenard. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Anna Huguenard · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Subarachnoid Hemorrhage with a site in United States — 31 open to participants now, 37 under way, 2 of them phase 3. Subarachnoid Hemorrhage · United States.

Planned enrollment
37th of 107
50 · median 30
Started
2021
with 5 others
No phase
34 of 149
7 open now
Primary completion
2026-03
later than 5 of 36 live
Registered
113th of 149
by date

Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, this one is the 37th largest by planned enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2021, is one of 34 with no phase, reaches primary completion later than 5 of the 36 other live ones, and was the 113th registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

31 of the 149 studies in Subarachnoid Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Subarachnoid Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate whether non-invasive auricular vagal nerve stimulation lowers inflammatory markers, and improves outcomes following spontaneous subarachnoid hemorrhage.

Read the detailed description

Vagal nerve stimulation (VNS) has been studied in several inflammatory conditions, and has been implemented in animal models of subarachnoid hemorrhage (SAH) with promising results. The purpose of the proposed study is to determine how applying auricular VNS in patients presenting with spontaneous SAH impacts their expression of inflammatory markers in their blood and cerebrospinal fluid (CSF), and how it impacts their clinical course and outcomes.

This study will involve randomizing patients to stimulation with VNS, or sham stimulation. Blood and CSF will be collected on admission, and serially throughout the patient's admission. Clinical events tracked during the hospital stay include development of cerebral vasospasm, need for CSF diversion via a shunt, stress-induced cardiomyopathy, and development of stroke or global cerebral ischemia. Outcomes following admission will include functional scores at discharge, and at follow-up visits for up to 2 years after discharge.

03

Conditions studied

  • Subarachnoid Hemorrhage

Keywords

  • Vagal nerve stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Spontaneous subarachnoid hemorrhage

Exclusion criteria

Exclusion Criteria:

  • Trauma-induced subarachnoid hemorrhage
  • Ongoing chemotherapy
  • Taking medications for other medical illnesses
  • Presence of a pacemaker
  • Prolonged bradycardia at time of admission
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Auricular VNS Stimulation

    Participants receive twice daily auricular vagal nerve stimulation

    Device: Auricular Vagus Nerve Stimulation

  • Sham comparator
    Sham Auricular VNS Stimulation

    Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied

    Device: Sham Auricular Vagus nerve Stimulation

Interventions

  • DeviceAuricular Vagus Nerve Stimulation

    Transcutaneous auricular vagal nerve stimulation

  • DeviceSham Auricular Vagus nerve Stimulation

    Transcutaneous auricular vagal nerve ear clip applied without current

06

What researchers measure

Primary outcomes

  1. Inflammatory markers in the serum on admission

    TNF alpha from blood draw

    Time frame: On hospital day 1

  2. Change in inflammatory markers in the serum

    TNF alpha from blood draws

    Time frame: Through hospital admission, average of 4 weeks

  3. Inflammatory markers in the CSF on admission

    TNF alpha from cerebrospinal fluid

    Time frame: On hospital day 1

  4. Change in inflammatory markers in the CSF

    TNF alpha from cerebrospinal fluid

    Time frame: Through hospital admission, average of 4 weeks

  5. Cerebral vasospasm

    Presence of moderate/severe radiographic vasospasm

    Time frame: Through hospital admission, average of 4 weeks

  6. Hydrocephalus

    Need for permanent CSF diversion via a ventricular shunt

    Time frame: Through hospital admission, average of 4 weeks

Secondary outcomes

  1. Inflammatory markers in the serum on admission

    IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8from blood draws

    Time frame: On hospital day 1

  2. Change in inflammatory markers in the serum

    IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8 from blood draws

    Time frame: Through hospital admission, average of 4 weeks

  3. Inflammatory markers in the CSF on admission

    IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8, from cerebrospinal fluid

    Time frame: On hospital day 1

  4. Change in inflammatory markers in the CSF

    IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8, from cerebrospinal fluid

    Time frame: Through hospital admission, average of 4 weeks

  5. Cerebral vasospasm

    Additional features of vasospasm: 1) Number of vascular studies obtained, 2) Need for blood pressure augmentation or hypervolemia, 3) Need for intraarterial or intrathecal vasodilator, 4) Need for angioplasty

    Time frame: Through hospital admission, average of 4 weeks

  6. Cerebral ischemia

    Presence of cerebral ischemia based on the following criteria: Radiographic evidence of a new infarct or stroke

    Time frame: Through hospital admission, average of 4 weeks

  7. Hydrocephalus

    Duration of temporary CSF diversion via an external ventricular drain

    Time frame: Through hospital admission, average of 4 weeks

  8. Clinical outcome

    Modified Rankin Scale for Neurological Disability (minimum score 0, maximum score 6, better outcomes have lower scores)

    Time frame: 2 years

  9. Stressed-induced cardiomyopathy

    Presence of stressed-induced cardiomyopathy based on any of the following criteria: 1) New troponin elevation, 2) New EKG changes (specifically ST segment elevation, ST segment depression, left bundle branch block, prolonged QT interval), 3) New findings of cardiomyopathy on echocardiogram

    Time frame: Through hospital admission, average of 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Tan G, Huguenard AL, Donovan KM, Demarest P, Liu X, Li Z, Adamek M, Lavine K, Vellimana AK, Kummer TT, Osbun JW, Zipfel GJ, Brunner P, Leuthardt EC. The effect of transcutaneous auricular vagus nerve stimulation on cardiovascular function in subarachnoid hemorrhage patients: A randomized trial. Elife. 2025 Jan 9;13:RP100088. doi: 10.7554/eLife.100088. PubMed 39786346 ↗
  • Huguenard A, Tan G, Johnson G, Adamek M, Coxon A, Kummer T, Osbun J, Vellimana A, Limbrick D Jr, Zipfel G, Brunner P, Leuthardt E. Non-invasive Auricular Vagus nerve stimulation for Subarachnoid Hemorrhage (NAVSaH): Protocol for a prospective, triple-blinded, randomized controlled trial. PLoS One. 2024 Aug 23;19(8):e0301154. doi: 10.1371/journal.pone.0301154. eCollection 2024. PubMed 39178291 ↗
  • Huguenard AL, Tan G, Rivet DJ, Gao F, Johnson GW, Adamek M, Coxon AT, Kummer TT, Osbun JW, Vellimana AK, Limbrick DD, Zipfel GJ, Brunner P, Leuthardt EC. Auricular Vagus Nerve Stimulation Mitigates Inflammation and Vasospasm in Subarachnoid Hemorrhage: A Randomized Trial. medRxiv [Preprint]. 2024 May 1:2024.04.29.24306598. doi: 10.1101/2024.04.29.24306598. PubMed 38746275 ↗
  • Tan G, Huguenard AL, Donovan KM, Demarest P, Liu X, Li Z, Adamek M, Lavine K, Vellimana AK, Kummer TT, Osbun JW, Zipfel GJ, Brunner P, Leuthardt EC. The effect of transcutaneous auricular vagus nerve stimulation on cardiovascular function in subarachnoid hemorrhage patients: a safety study. medRxiv [Preprint]. 2024 Sep 8:2024.04.03.24304759. doi: 10.1101/2024.04.03.24304759. PubMed 38633771 ↗
  • Huguenard AL, Tan G, Johnson GW, Adamek M, Coxon AT, Kummer TT, Osbun JW, Vellimana AK, Limbrick DD Jr, Zipfel GJ, Brunner P, Leuthardt EC. Non-invasive Auricular Vagus nerve stimulation for Subarachnoid Hemorrhage (NAVSaH): Protocol for a prospective, triple-blinded, randomized controlled trial. medRxiv [Preprint]. 2024 Mar 19:2024.03.18.24304239. doi: 10.1101/2024.03.18.24304239. PubMed 38562875 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Mar 2026, 62 months.

Of 59 non-industry interventional studies with no phase under Subarachnoid Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 69. This study's 62 months is above that.

Counting every sponsor, half of 69 studies reached it within 32 months; a quarter within 20 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jun 2026 → Mar 2026 and completion Dec 2028 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 21, 2020
StartActual
Jan 5, 2021
Primary completionActual
Mar 15, 2026was Jun 2026
CompletionEst.
Mar 15, 2028was Dec 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 27, 2026
Primary completion
Jun 2026→Mar 15, 2026 (actual)
Oct 27, 2026
Study completion
Dec 2028→Mar 15, 2028
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 2026→Mar 15, 2026 (now actual)
    Study completion Dec 2028→Mar 15, 2028
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04557618
Lead sponsor
Anna Huguenard
Responsible party
Anna Huguenard (Assistant Professor of Neurosurgery, Washington University School of Medicine) — Sponsor-investigator
First posted
Sep 21, 2020
Start date
Jan 5, 2021
Primary completion
Mar 15, 2026
Completion
Mar 15, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Eric C Leuthardt, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion